Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020026 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07020026 is a Phase 2 study of Parkinson's Disease that is actively recruiting participants, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 60 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07020026, a Phase 2 study of Parkinson's Disease, is actively recruiting participants, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.
Conditions Studied
Interventions
- DRUG [18F]PI-2620
Study Locations (1)
Connecticut
- Institute for Neurodegenerative Disorders / XingImaging, LLC - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07020026
The ClinicalTrials.gov registry entry for NCT07020026 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (91% lower). The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]PI-2620 is the first listed.
NCT07020026 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07020026 about?
NCT07020026 is a clinical study titled "Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease". The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.
What is the current status of trial NCT07020026?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-05-12. Estimated completion is 2027-06.
What conditions does trial NCT07020026 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT07020026?
The interventions under investigation include: [18F]PI-2620 (DRUG).
Who is sponsoring clinical trial NCT07020026?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020026 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.